ESCC

1 stories · following the connections

Business

Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USA

By Nasdaq OMXOct 24, 2017, 11:00 AM UTC